Trelegy® Ellipta® is used to treat moderate to severe chronic obstructive pulmonary disease (COPD) or asthma. COPD is a group of diseases that affect your lungs and airways, causing breathing difficulties. The 2 main types of COPD are emphysema and chronic bronchitis. Learn more about COPD and medicines for COPD.
Trelegy Ellipta contains 3 medicines (fluticasone, umeclidinium and vilanterol) mixed in 1 inhaler.
- Fluticasone reduces swelling and irritation in the airways in the lungs. It belongs to a group of medicines known as inhaled corticosteroids.
- Umeclidinium and vilanterol work together to relax the muscles in your airways. This helps to open your airways and makes it easier for airflow in and out of your lungs.
The benefit of having 3 medicines in a single inhaler means you only need to use 1 inhaler instead of 2 or 3. You won't need to use other 'preventer' inhalers for your COPD.
- Trelegy Ellipta is a dry powder inhaler.
- The powder is breathed in through your mouth using the inhaler device, so the medicine can go straight into your airways and lungs and very little of the medicine gets to the rest of your body.
Funding in New Zealand
- From 1 May 2024, Trelegy Ellipta is funded for people with moderate to severe COPD who are using 2 or 3 inhalers daily and meet other criteria. Talk to your healthcare provider to see if Trelegy Ellipta is suitable for you.
- Note: Trelegy Ellipta inhaler comes in 2 strengths but only the lower strength is funded. This is fluticasone furoate 100 mcg with umeclidinium 62.5 mcg and vilanterol 25 mcg which is the strength used for COPD.
Trelegy Ellipta is a long-term treatment and doesn't give immediate relief from sudden breathing problems, eg, wheezing, tight chest and shortness of breath
|
Factsheet: Trelegy Ellipta for COPD
Trelegy Ellipta for COPD English [PDF, 430 KB] |